IQVIA

• NCT05264506

  Collaborator, Phase 3, Terminated, 3,055 people, 3 Mar 2022

• NCT04498117

  Collaborator, Phase 3, Active, not recruiting, 615 people, 4 Aug 2020

• NCT04246762

  Collaborator, Phase 1, Completed, 17 people, 29 Jan 2020

• NCT03980483

  Collaborator, Phase 3, Completed, 1,537 people, 10 Jun 2019

• NCT03970837

  Collaborator, Phase 3, Terminated, 1,764 people, 3 Jun 2019

• NCT03544281

  Collaborator, Phase 1/2, Completed, 153 people, 1 Jun 2018

• European Commission

  HORIZON-JU-RIA, Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health, 101192133, 2025–2030, 8 May 2025

Sources: cordis.europa.eu

• Disrupted daily rhythms in light exposure and wrist temperature are associated with metabolic risk markers and obesity

  Employment, 10 Oct 2026

• Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial

  Fees or honoraria, 8 Oct 2026

• Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

  Fees or honoraria, 28 Sept 2026

• Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2

  Consulting or advice, Fees or honoraria, 17 Sept 2026

• Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach

  Employment, 10 Sept 2026

• Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies

  Consulting or advice, Fees or honoraria, 9 Sept 2026

• Herpes zoster incidence rates in adults aged 18 years or older with immunocompromising or chronic conditions in England: a large retrospective cohort study (Clinical Practice Research Datalink, 2012-2019)

  Employment, 8 Sept 2026

• Integrating frailty into decision-making for disease-modifying therapies in Alzheimer's disease: a proposed expert-opinion based approach

  Consulting or advice, 4 Sept 2026

• Gaps in lipid management among high-risk patients without prior MI or stroke: the VESALIUS-REAL global study

  Grants or research support, 3 Sept 2026

• Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study

  Employment, 1 Sept 2026

• Burden of chronic kidney disease and outcomes following hospitalisation for heart failure

  Consulting or advice, Fees or honoraria, 25 Aug 2026

• Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

  Grants or research support, 18 Aug 2026

• From screening to surveillance: integrated prevention of Helicobacter pylori-associated gastric cancer in the Asia-Pacific region

  Consulting or advice, 17 Aug 2026

• Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis

  Fees or honoraria, Grants or research support, Board or leadership role, 7 Aug 2026

• Voxelwise correlation of neighbors as a hypothesis driven framework for characterizing white matter lesion heterogeneity

  Consulting or advice, 8 Jan 2026

• Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas

  Employment, 24 Oct 2025

• Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK Biobank

  Grants or research support, 1 Jul 2023

Sources: pubmed.ncbi.nlm.nih.gov

• SGLT2 Inhibitor Adherence and Diabetes Hospitalization Risk in Type 2 Diabetes

  The American journal of managed care, 30 Sept 2026

• Epidemiological Studies on Type 2 Diabetes Using the German Disease Analyser Database: A Narrative Review

  Diabetes, obesity & metabolism, 7 Jul 2026

• Real-World Impact of Oral Semaglutide (SEMA) vs. DPP-4 Inhibitors on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025